WINDTREE THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1992-11-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.windtreetx.com
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Phase 2
Completed
- Conditions
- Acute Hypoxemic Respiratory Failure
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 165
- Registration Number
- NCT00578734
- Locations
- 🇨🇱
Call For Information, Santiago, Chile
🇺🇸Call for information, Warrington, Pennsylvania, United States
🇨🇱Call for Information, Concepcion, Chile
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
Phase 2
Terminated
- Conditions
- Respiratory Distress Syndrome, NewbornPremature BirthBronchopulmonary Dysplasia
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 136
- Registration Number
- NCT00215540
- Locations
- 🇺🇸
Discovery Laboratories, Inc., Warrington, Pennsylvania, United States
KLâ‚„Surfactant Treatment in Patients With ARDS
Phase 2
Terminated
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 124
- Registration Number
- NCT00215553
- Locations
- 🇺🇸
Discovery Laboratories, Inc., Warrington, Pennsylvania, United States
Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 69
- Registration Number
- NCT00004500
- Locations
- 🇺🇸
Discovery Laboratories, Inc., Warrington, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath